Latest Trials Latest NewsFAQ

YALE UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1701-10-09

Employees: 10K

Market Cap: -

Website: http://www.yale.edu

Clinical Trials

Sensitivity to Intravenous Nicotine: Genetic Moderators

Phase 1

Completed

Conditions: Nicotine Dependence

Interventions: Drug: saline
Drug: Nicotine

First Posted Date: 2009-09-01

Last Posted Date: 2017-04-19

Lead Sponsor: Yale University

Target Recruit Count: 213

Registration Number: NCT00969137

Locations: 🇺🇸
Department of Veterans Affairs, West Haven, Connecticut, United States

Transvaginal Cholecystectomy Versus Laparoscopic Cholecystectomy in Patients With Biliary Colic

Not Applicable

Completed

Conditions: Biliary Colic

Interventions: Procedure: laparoscopic cholecystectomy
Procedure: transvaginal cholecystectomy

First Posted Date: 2009-08-24

Last Posted Date: 2018-01-17

Lead Sponsor: Yale University

Target Recruit Count: 30

Registration Number: NCT00963950

Positron Emission Tomography (PET) Imaging of Pancreatic Beta-Cell Mass in Healthy and Type 1 Diabetic Patients

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: 18F-FP-DTBZ (18F-AV-133)
Biological: Arginine-hydrochloride

First Posted Date: 2009-08-14

Last Posted Date: 2012-07-23

Lead Sponsor: Yale University

Target Recruit Count: 16

Registration Number: NCT00958997

Locations: 🇺🇸
Yale University School of Medicine, PET Center, New Haven, Connecticut, United States

Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects

Not Applicable

Completed

Conditions: Cognitive Aging

Interventions: Drug: Guanfacine
Drug: Placebo

First Posted Date: 2009-07-09

Last Posted Date: 2014-08-13

Lead Sponsor: Yale University

Target Recruit Count: 154

Registration Number: NCT00935493

Locations: 🇺🇸
Alzheimer's Disease Research Unit, Yale University School of Medicine, New Haven, Connecticut, United States

Smoking Cessation Treatment for Head and Neck Cancer Patients

Early Phase 1

Terminated

Conditions: Smoking Cessation

Interventions: Drug: Varenicline (Chantix)
Drug: Nicotine Patch

First Posted Date: 2009-07-02

Last Posted Date: 2013-07-15

Lead Sponsor: Yale University

Target Recruit Count: 7

Registration Number: NCT00931021

Locations: 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

Stress Reactivity in Veterans Receiving Pharmacological Treatment for PTSD and Alcohol Dependence

Not Applicable

Completed

Conditions: Post-traumatic Stress Disorder
Alcohol Dependence

Interventions: Behavioral: stress

First Posted Date: 2009-06-18

Last Posted Date: 2016-12-14

Lead Sponsor: Yale University

Target Recruit Count: 57

Registration Number: NCT00923923

Locations: 🇺🇸
VA Connecticut Healtcase System, West Haven, Connecticut, United States

Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy

Phase 2

Terminated

Conditions: Autosomal Dominant Polycystic Kidney Disease

Interventions: Other: Standard of Care-Placebo
Drug: Rapamycin

First Posted Date: 2009-06-15

Last Posted Date: 2014-04-14

Lead Sponsor: Yale University

Target Recruit Count: 21

Registration Number: NCT00920309

Locations: 🇺🇸
Yale Center for Clinical Investigation, New Haven, Connecticut, United States

Simulation Training for Ultrasound Guided Central Venous Catheter Insertion

Completed

Conditions: Procedural Skill Competency

Interventions: Other: Competency based simulation training

First Posted Date: 2009-06-12

Last Posted Date: 2020-03-31

Lead Sponsor: Yale University

Target Recruit Count: 184

Registration Number: NCT00919308

Locations: 🇺🇸
Yale-New Haven Hospital, New Haven, Connecticut, United States

Behavioral Treatment for Cocaine Dependent Women

Phase 2

Completed

Conditions: Cocaine Dependence

Interventions: Behavioral: Behavioral therapy

First Posted Date: 2009-06-05

Last Posted Date: 2020-03-31

Lead Sponsor: Yale University

Target Recruit Count: 145

Registration Number: NCT00914381

Locations: 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸
The APT Foundation, Inc. MRU, New Haven, Connecticut, United States

Disulfiram for Cocaine Abuse in Buprenorphine Treatment

Phase 2

Completed

Conditions: Cocaine Dependence
Opioid Dependency

Interventions: Drug: Disulfiram
Drug: Placebo

First Posted Date: 2009-06-04

Last Posted Date: 2020-11-19

Lead Sponsor: Yale University

Target Recruit Count: 177

Registration Number: NCT00913484

Locations: 🇺🇸
The APT Foundation MRU, New Haven, Connecticut, United States
🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy